Publications by authors named "Fabrice Barlesi"

Claim this Profile
S
Surrogate markers of intestinal dysfunction associated with survival in advanced cancers.
Roxanne Birebent, Damien Drubay, Carolina Alves Costa Silva, Federica Marmorino, Giacomo Vitali, Fabrice Barlesi

Oncoimmunology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final 3-year results from the EVIDENS study, an observational study of nivolumab in non-small cell lung cancer.
Fabrice Barlesi, Adrien Dixmier, Didier Debieuvre, Christophe Raspaud, Jean-Bernard Auliac

Oncoimmunology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline CT-derived tumor burden and liquid biopsy as biomarkers to predict survival in patients with metastatic solid cancer.
Ghina Jardali, Littisha Lawrance, Lama Dawi, Jules Dupont, Othilie Gautier, Fabrice Barlesi

Diagn Interv Imaging· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of the ALINA study results: alectinib compared with chemotherapy after surgery in people with -positive non-small cell lung cancer.
Yi-Long Wu, Rafal Dziadziuszko, Jin Seok Ahn, Fabrice Barlesi, Makoto Nishio

Future Sci OA· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations.
Tianshi Lu, Habib Hamidi, Mark A Socinski, Martin Reck, Federico Cappuzzo, Fabrice Barlesi

Nat Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of NSCLC after chemoimmunotherapy - are we making headway?
Martin Reck, Nikolaj Frost, Solange Peters, Bernard A Fox, Roberto Ferrara, Fabrice Barlesi

Nat Rev Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis.
Abderaouf Hamza, Pierre Gestraud, Maryam Karimi, Alicia Tran-Dien, Laurène Syx, Fabrice Barlesi

Br J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive molecular landscape of anal squamous cell carcinoma: analysis of tissue and liquid biopsies from 1844 patients.
Cristina Smolenschi, Saumya D Sisoudiya, Antoine Hollebecque, Smruthy Sivakumar, Meagan Montesion, Fabrice Barlesi

NPJ Precis Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5.
Anas Gazzah, Charles Ricordel, Antoine Italiano, Byoung Chul Cho, Emiliano Calvo, Fabrice Barlesi

JTO Clin Res Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies.
Bob T Li, Leena Gandhi, Vignesh Ravichandran, Benjamin Besse, Julien Mazières, Fabrice Barlesi

Clin Lung Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to letter Re "Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS".
Elisa Gobbini, Alexandra Langlais, Pascale Missy, Sébastien Chanoine, Benjamin Besse, Fabrice Barlesi

Eur J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung Cancer.
Adrien Rousseau, Noémie Simon-Tillaux, Stefan Michiels, Lisa Derosa, Ariane Laparra, Fabrice Barlesi

JAMA Netw Open· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The correlation of liquid biopsy genomic data to radiomics in colon, pancreatic, lung and prostatic cancer patients.
Antoine Italiano, Othilie Gautier, Jules Dupont, Tarek Assi, Lama Dawi, Fabrice Barlesi

Eur J Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adagrasib versus docetaxel in KRAS-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial.
Fabrice Barlesi, Wenxiu Yao, Michaël Duruisseaux, Ludovic Doucet, Aitor Azkárate Martínez

Lancet· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung Cancer.
Arianna Marinello, Maria Rosa Ghigna, Julia K Rotow, Tolulope Adeyelu, Giulio Metro, Fabrice Barlesi

JAMA Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS.
Elisa Gobbini, Alexandra Langlais, Pascale Missy, Sébastien Chanoine, Benjamin Besse, Fabrice Barlesi

Eur J Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial.
Charu Aggarwal, Alex Martinez-Marti, Margarita Majem, Fabrice Barlesi, Enric Carcereny

JAMA Netw Open· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers.
Roman M Chabanon, Liudmila Shcherbakova, Magali Lacroix-Triki, Marine Aglave, Jean Zeghondy, Fabrice Barlesi

Nat Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world characteristics and survival outcomes of patients with metastatic ALK fusion-positive solid tumors treated with standard-of-care therapies.
Shirish M Gadgeel, Otto Fajardo, Fabrice Barlesi, Jeong Eun Kim, Razelle Kurzrock

Oncologist· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infectious Complications in Patients Treated with T-cell Engagers as Cancer Immunotherapies, A Descriptive Study from the REISAMIC Registry.
Thomas Hueso, Justin Cagnat, Kaïssa Ouali, Mathilde Haberstich, Benoît Henry, Fabrice Barlesi

Clin Infect Dis· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience.
Claudia Parisi, José Carlos Benitez, Hélène Lecourt, Filippo Gustavo dall'Olio, Mihaela Aldea, Fabrice Barlesi

J Liq Biopsy· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.
Armando Santoro, Garrido Pilar, Daniel S W Tan, Jon Zugazagoitia, Frances A Shepherd, Fabrice Barlesi

BMC Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liquid Biopsy versus CT: Comparison of Tumor Burden Quantification in 1065 Patients with Metastases.
Lama Dawi, Younes Belkouchi, Littisha Lawrance, Othilie Gautier, Samy Ammari, Fabrice Barlesi

Radiology· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancer.
Filippo G Dall'Olio, Wael Salem Zrafi, Quentin Blampey, Francois-Xavier Danlos, Matthieu Roulleaux-Dugage, Fabrice Barlesi

J Immunother Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.
Armando Santoro, Garrido Pilar, Daniel S W Tan, Jon Zugazagoitia, Frances A Shepherd, Fabrice Barlesi

BMC Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis